Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt-1, VEGF-R2-KDR/Flk-1) as prognostic indicators in small cell lung carcinomas (SCLC) Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) as a prognostic factor of survival in patients with lung adenocarcinoma Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Investigating new prognostic crossroads in lung carcinomas; comparing the prognostic potential of vascular endothelial growth factor (VEGF) and its receptors versus endoglin (CD105) Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009
Vascular endothelial growth factor (VEGF) expression in non small cell lung cancer and its association with histopathologic type, stage, lymphnode involvement, recurrence and distant metastasis Source: Eur Respir J 2003; 22: Suppl. 45, 393s Year: 2003
Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007
The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis. Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes Year: 2018
Comparing the prognostic impacts of angiogenesis, lymphangiogenesis and lymphatic invasion (LI) in small cell lung carcinomas (SCLC) Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Comparing LYVE-1 and D2-40 expression in small cell lung carcinomas (SCLC); association with clinical parameters and lymphatic invasion Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
Inverse correlation between the expression of vascular endothelial growth factor and infiltration of dendritic cells and their influence on the prognosis of nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 13s Year: 2002
Production of a novel isoform of vascular endothelial growth factor (VEGF) by the normal human lung Source: Eur Respir J 2006; 28: Suppl. 50, 822s Year: 2006
Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009
Expression of vascular endothelial-cadherin and vascular endothelial growth factor in non-small cell lung cancer and their clinical significances Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012
The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Vascular endothelial growth factor (VEGF) is a predictable marker for FEV1 progression in patients with Lymphangiolyomyomatosis (LAM). Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019
C-kit (CD 117): a new prognostic factor in small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001
Changes and significance of hepatoma-derived growth factor and vascular endothelial growth factor in serum and lung tissue from patients with lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010